phenyl 4-ethylpiperidine-1-carboxylate | 651053-80-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: phenyl 4-ethylpiperidine-1-carboxylate
• CAS: 651053-80-4
• 化学式: C₁₄H₁₉NO₂
• 分子量: 233.31
• InChiKey: OCOABNJDRGLSTD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  phenyl 4-ethylpiperidine-1-carboxylate 在 氢氧化钾 、 一水合肼 作用下， 以 乙二醇 为溶剂， 反应 1.0h， 以60%的产率得到4-乙基哌啶
  参考文献：
  名称：

  4-取代氮保护哌啶的高效液相平行合成

  摘要：

  通过CuCN·2LiBr催化的有机锌加成到1-酰基吡啶盐和随后的氢转移氢合成4-取代的N-保护的哌啶的实际条件...

  DOI：

  10.1002/ejoc.200300387
• 作为产物：
  描述：

  氯甲酸苯酯 在 palladium on activated charcoal ammonium formate 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 1.0h， 生成 phenyl 4-ethylpiperidine-1-carboxylate
  参考文献：
  名称：

  4-取代氮保护哌啶的高效液相平行合成

  摘要：

  通过CuCN·2LiBr催化的有机锌加成到1-酰基吡啶盐和随后的氢转移氢合成4-取代的N-保护的哌啶的实际条件...

  DOI：

  10.1002/ejoc.200300387

文献信息

• Tri-cycle compound and applications thereof
  申请人：FUJIAN COSUNTER PHARMACEUTICAL CO., LTD.

  公开号：US11053260B2

  公开（公告）日：2021-07-06

  Disclosed in the present invention are a compound represented by formula (I), a tautomer thereof or a pharmaceutically acceptable salt, and applications thereof in the preparation of drugs for treating HBV-related diseases.

  本发明公开了一种由式（I）代表的化合物、其同系物或药学上可接受的盐，以及其在制备治疗 HBV 相关疾病药物中的应用。
• METHOD TO TREAT SICKLE CELL DISEASE
  申请人：Linden M. Joel

  公开号：US20080009460A1

  公开（公告）日：2008-01-10

  The present invention provides a therapeutic method for treating an inflammatory response caused by a sickle cell crisis, comprising administration of an effective amount amount of an A 2A adenosine receptor agonist. Optionally, the method includes administration of a type IV PDE inhibitor (e.g., rolipram).
• METHOD TO TREAT GASTRIC LESIONS
  申请人：Linden M. Joel

  公开号：US20080027022A1

  公开（公告）日：2008-01-31

  The present invention provides a therapeutic method for treating gastric lesions, including administration to a patient in need thereof of an effective amount of an A 2A adenosine receptor agonist. The A 2A adenosine receptor agonist can be a compound of formula (I) as disclosed herein. The invention further provides a therapeutic method for treating the patient with an A 2A adenosine receptor agonist, optionally, in combination with a Type IV phosphodiesterase (PDE) inhibitor. In one embodiment, the gastric lesions are caused by, or aggravated by, the use of NSAIDS such as, for example, aspirin.
• MEDICAMENT FOR SUPPRESSING MALIGNANT TUMOR METASTASIS
  申请人：NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER

  公开号：US20170014419A1

  公开（公告）日：2017-01-19

  Provided are a novel medicament for suppressing or preventing the metastasis of a malignant tumor such as carcinoma, a novel treatment or prevention method for suppressing or preventing the metastasis of a malignant tumor, etc. The medicament comprises a non-peptidic angiotensin type 2 receptor agonist as an active ingredient. In the medicament, the non-peptidic angiotensin type 2 receptor agonist may be, for example, a sulfonyl malonamide compound. The medicament may be a medicament for use in combination with an anticancer agent and/or an antitumor agent.
• UREA/CARBAMATES FAAH MAGL OR DUAL FAAH/MAGL INHIBITORS AND USES THEREOF
  申请人：Northeastern University

  公开号：US20170247387A1

  公开（公告）日：2017-08-31

  Disclosed are compounds that may be used to inhibit the action of fatty acid amide hydrolase (FAAH), monoacylglycerol lipase (MAGL) or dual FAAH/MAGL.